Lepu Biopharma Co., Ltd. (HKG:2157)
Hong Kong · Delayed Price · Currency is HKD 6.20
-0.31 (-4.76%)
Apr 17, 2026, 11:59 AM HKT
Lepu Biopharma Revenue
In the year 2025, Lepu Biopharma had annual revenue of 934.87M CNY with 154.18% growth. Lepu Biopharma had revenue of 468.93M in the half year ending December 31, 2025, with 553.11% growth.
Revenue
934.87M CNY
Revenue Growth
+154.18%
P/S Ratio
11.29
Revenue / Employee
1.71M CNY
Employees
546
Market Cap
11.75B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 934.87M | 567.08M | 154.18% |
| Dec 31, 2024 | 367.79M | 142.44M | 63.21% |
| Dec 31, 2023 | 225.35M | 209.78M | 1,347.16% |
| Dec 31, 2022 | 15.57M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 5.41B |
| Shanghai Haohai Biological Technology | 2.72B |
| Everest Medicines | 1.90B |
| HBM Holdings | 1.23B |
| Ocumension Therapeutics | 895.09M |
| Abbisko Cayman | 681.17M |
| Alphamab Oncology | 630.11M |
| CStone Pharmaceuticals | 299.99M |